Search results for "Pharmacologic Substance[C1909]|Enzyme Inhibitor[C471]|SGLT2 Inhibitor" in comments (approximate match)
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Tofogliflozin is a SGLT2 selective inhibitor which was developed by Chugai Pharmaceutical for the treatment of Type 2 Diabetes Mellitus. The drug was approved in Japan in 2013 and it is being marketed under the names Apleway and Debereza.